- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01912976
Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Bowen's Disease
A Randomized, Intra-individual, Prospective Study Comparing Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Ablative Fractional Laser Treatment in Asian Patients With Lower Extremity Bowen's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Bowen's disease (BD) is a form of intraepidermal (in situ) squamous cell carcinoma (SCC) originally described in 1912.1 It presents as a gradually enlarging, well-demarcated erythematous plaque with an irregular border and surface crusting or scaling.2 BD is the frequent precancerous skin lesion in Caucasians.3 In the UK, BD occurrence is most common among patients in their 70s and in women (70-85%), and the majority (60-85%) of cases involve lesions of the lower leg.4,5 BD is estimated to evolve into invasive SCC in 3-5% of cases; therefore, treatment is recommended.6 Current guidelines suggest that the available therapeutic options (including cryotherapy, curettage, excision, topical 5-fluorouracil, and topical imiquimod) are broadly similar in efficacy, with 12-month recurrence rates of approximately 5-10%.7 However, cryotherapy can be painful, making treatment of multiple lesions difficult, and healing can be slow.8 Additionally, topical treatment with 5-fluorouracil or imiquimod is relatively slow and typically causes local irritation.9,10 Photodynamic therapy (PDT) with methyl aminolaevulinate (MAL) is an attractive treatment option for BD with large or multiple patches, and poor healing sites can be treated with good efficacy, low recurrence rates, and good cosmetic outcomes.7 PDT requires light activation of a photosensitizer in the presence of oxygen, which generates reactive oxygen species leading to selective and highly localized destruction of abnormal cells.11,12 MAL is an efficient photosensitizer, with deep lesion penetration resulting from enhanced lipophilicity. Compared to 5-aminolevulinic acid, MAL also has a greater specificity for neoplastic cells.13-15 Because histologic features of BD include full-thickness keratinocyte atypia with disordered maturation, it is typically treated twice within an interval of 1 week.16,17 So, complementary techniques are needed to enhance the penetration and accumulation of MAL in order to improve PDT efficacy and decrease treatment duration.
Er:YAG ablative fractional laser therapy (AFL) can ablate the stratum corneum in a precisely tuned manner without producing significant thermal injury. This approach creates microscopic vertical holes in the ablated tissue, surrounded by thin layers of coagulated tissue.18,19 Since the Er:YAG AFL resurfaces 5-20% of the skin at one time and does not injure the entire thickness of the epidermis, healing times are minimized.18,19 Recent studies have demonstrated that AFL facilitates delivery and uptake of topical MAL deep into the skin, enhancing porphyrin synthesis and photodynamic activation.20,21 The objectives of this study were to compare the efficacy, recurrence rate, cosmetic outcomes, and safety of MAL-PDT with and without the use of Er:YAG AFL in Asian BD patients with multiple lower extremity lesions.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Dong dae sin-dong, Seo-gu
-
Busan, Dong dae sin-dong, Seo-gu, Korea, Republic of, 602-715
- Dong-A University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Korean patients aged ≥ 18 years who had biopsy-confirmed BD lesions on the lower extremities
Exclusion Criteria:
- porphyria,
- known allergies to the MAL cream or lidocaine,
- pregnancy,
- lactation,
- any active systemic infectious disease,
- immunosuppressive treatment,
- personal history of malignant melanoma,
- tendency towards melasma or keloid formation,
- prior treatment of the lesions within 4 weeks, and
- any indication of poor compliance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Er:YAG AFL-PDT
Right leg on each patients was assigned a single session of Er:YAG AFL-PDT.
|
Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse.
MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
Other Names:
|
Active Comparator: MAL-PDT
Left leg on each patient was selected to receive 2 sessions of MAL-PDT
|
a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue.
The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2.
Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference the efficacy between Er:YAG AFL-assisted MAL-PDT (Er:YAG AFL-PDT) and standard MAL-PDT.
Time Frame: Efficacy was evaluated at 3 months and 12 months after treatment
|
Lesion response was classified as either complete (complete disappearance of the lesion) or incomplete (incomplete disappearance) on the basis of visual examination and palpation.
The response of each lesion was clinically evaluated
|
Efficacy was evaluated at 3 months and 12 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference of the cosmetic outcomes between Er:YAG AFL-assisted MAL-PDT (Er:YAG AFL-PDT) and standard MAL-PDT.
Time Frame: Cosmetic outcome was assessed by each investigator for all lesions that achieved a complete response at 3 or 12 months
|
It was graded using a 4-point scale: excellent (only slight occurrence of redness or change in pigmentation), good (moderate redness or change in pigmentation), fair (slight-to-moderate scarring, atrophy, or induration), or poor (extensive scarring, atrophy, or induration)
|
Cosmetic outcome was assessed by each investigator for all lesions that achieved a complete response at 3 or 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference of the recurrence rates and safety between Er:YAG AFL-assisted MAL-PDT (Er:YAG AFL-PDT) and standard MAL-PDT.
Time Frame: within 12 months after both treatment
|
If the case of complete response of lesions, all patients were reviewed at 12 months to check recurrence. Adverse events reported by the patient were noted at each follow-up visit, including severity, duration, and need for additional therapy. All events due to PDT were described as phototoxic reactions (i.e. erythema, postinflammatory hyperpigmentation, oedema, itching, oozing, bleeding, etc.). |
within 12 months after both treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ki-Hoon Song, M.D., Ph.D., Assistant professor and Chariman, Department of dermatology Dong-A University, College of medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DAUDerma-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bowen's Disease
-
Brooke Army Medical CenterUnknown
-
National Taiwan University HospitalUnknown
-
Maastricht University Medical CenterRecruiting
-
Dong-A UniversityCompleted
-
Catharina Ziekenhuis EindhovenErasmus Medical CenterTerminated
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...UnknownKeratotic Nodular SizeBangladesh
-
SirnaomicsAmarex Clinical ResearchCompletedOpen Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCCBowen's Disease | Cutaneous Squamous Cell Carcinoma in SituUnited States
-
University of DundeeCompletedBasal Cell Carcinoma | Bowen's DiseaseUnited Kingdom
-
Maastricht University Medical CenterActive, not recruitingKeratosis, Actinic | Actinic Keratoses | Diagnosis | Bowen's Disease | Cutaneous Squamous Cell CarcinomaNetherlands
-
G&E Herbal Biotechnology Co., LTDCompletedActinic Keratosis | Bowen's DiseaseTaiwan
Clinical Trials on Er:YAG AFL-PDT
-
Dong-A UniversityCompletedNodular Basal Cell CarcinomaKorea, Republic of
-
Dong-A UniversityCompletedActinic CheilitisKorea, Republic of
-
Dong-A UniversityCompletedActinic KeratosisKorea, Republic of
-
San Diego State UniversityArizona State UniversityCompletedPhysical Activity | Cardiovascular FitnessUnited States
-
University of MiamiWithdrawn
-
Rambam Health Care CampusCompleted
-
Damascus UniversityCompletedClass II Division 1 Malocclusion | Protrusion, Incisor | Maxillary PrognathismSyrian Arab Republic
-
University Hospital Inselspital, BerneWithdrawnLupus Erythematosus, CutaneousSwitzerland
-
University Of PerugiaCompletedDental Caries | Microbial ColonizationItaly